An explorative study on deep profiling of peripheral leukocytes to identify predictors for responsiveness to anti-tumour necrosis factor alpha therapies in ankylosing spondylitis: natural killer cells in focus
Abstract Background Therapeutic targeting of tumour necrosis factor (TNF)-α is highly effective in ankylosing spondylitis (AS) patients. However, since one-third of anti-TNF-treated AS patients do not show an adequate clinical response there is an urgent need for new biomarkers that would aid clinic...
Main Authors: | Ursula Schulte-Wrede, Till Sörensen, Joachim R. Grün, Thomas Häupl, Heike Hirseland, Marta Steinbrich-Zöllner, Peihua Wu, Andreas Radbruch, Denis Poddubnyy, Joachim Sieper, Uta Syrbe, Andreas Grützkau |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-08-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13075-018-1692-y |
Similar Items
-
Ankylosing spondylitis and psoriatic arthritis: clinical and economic consequences of the use of etanercept
by: Viola Sacchi, et al.
Published: (2010-06-01) -
CLINICAL EXPERIENCE WITH ETANERCEPT IN THE TREATMENT OF PATIENTS WITH ANKYLOSING SPONDYLITIS
by: O. A. Rumyantseva, et al.
Published: (2018-05-01) -
Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial
by: James Cheng-Chung Wei, et al.
Published: (2020-10-01) -
Serum levels of leptin and high molecular weight adiponectin are inversely associated with radiographic spinal progression in patients with ankylosing spondylitis: results from the ENRADAS trial
by: Agnes Hartl, et al.
Published: (2017-06-01) -
Comparative Efficacy and Acceptability of Anti-TNF-Alpha Therapy in Ankylosing Spondylitis: A Mixed-Treatments Comparison
by: Yehua Wang, et al.
Published: (2016-09-01)